SHANGHAI, April 9, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the first cohort of healthy volunteers has been dosed in a phase I clinical trial of AK0406, a novel long-acting antiviral drug-Fc conjugate (ADFC) drug for influenza...
Hence then, the article about arkbio completed dosing of first cohort in australian phase i trial of antiviral drug fc conjugate drug ak0406 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( ArkBio Completed Dosing of First Cohort in Australian Phase I Trial of Antiviral Drug-Fc Conjugate Drug AK0406 )
Also on site :
- The Nord Stream narrative explosion: Why you’ve only read half the story
- 2011 Concert Ended in Boos Just Weeks Before Iconic Singer's Death
- This 'Lightweight and Hydrating' Moisturizer Is a Frequent Repurchase for Ulta Shoppers—and It's Just $16